Clinical Trial Update: Dapagliflozin for Anemia in Lower-Risk Myelodysplastic Syndromes [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating dapagliflozin for treating anemia in patients with lower-risk myelodysplastic syndromes, currently not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Myelodysplastic Syndromes

Drugs mentioned

• Dapagliflozin (Farxiga) (dapagliflozin)

Snippet

Sponsor: Seug yun Yoon, MD | Conditions: Myelodysplastic Syndromes (MDS), Anemia | Phase 2 | Status: NOT_YET_RECRUITING